BIOREM: Die „unentdeckte Perle“ am Aktienmarkt - 500 Beiträge pro Seite
eröffnet am 11.08.20 18:41:48 von
neuester Beitrag 02.02.22 15:21:09 von
neuester Beitrag 02.02.22 15:21:09 von
Beiträge: 17
ID: 1.329.244
ID: 1.329.244
Aufrufe heute: 0
Gesamt: 1.040
Gesamt: 1.040
Aktive User: 0
ISIN: CA09068G1046 · WKN: A0EQ63 · Symbol: BRM
2,0000
CAD
-3,85 %
-0,0800 CAD
Letzter Kurs 25.04.24 TSX Venture
Werte aus der Branche Industrie/Mischkonzerne
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 27,60 | +57,71 | |
| 1,5500 | +17,42 | |
| 15,600 | +13,54 | |
| 0,5275 | +9,90 | |
| 1,6120 | +8,48 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 79,16 | -9,88 | |
| 10,148 | -10,61 | |
| 0,5283 | -11,63 | |
| 21,700 | -13,27 | |
| 3,6000 | -14,29 |
Feedback
Biorem's revenues for the second quarter were $5.9 million a 14% decrease over the previous quarter and on par with the $5.9 million of revenues reported in the same quarter in 2019. Year to date revenues totalled $12.9 million, a 22% increase over the $10.0 million reported for the first six months of 2019. The increase in revenues for the first six months of 2020 was due to a $30 million order backlog at the beginning of the year compared to a $22 million order backlog at the beginning of 2019.
Gross profit for the quarter was $1.4 million or 23.9% of revenue compared to $1.3 million of gross profit representing 22.5% of revenue recorded during the second quarter of 2019. Total operating expenses (net of other income) for the quarter were $961,000 against $1,079,000 in the same period the prior year. The decrease in operating expenses was primarily due to a decrease in sales travel expenses related to the Covid19 pandemic. Ebitda for the quarter was $504,000 compared to $295,000 of ebitda in the second quarter of 2019.
Net earnings for the quarter were $338,000, with year to date earnings totalling $801,000 compared to net earnings of $139,000 for the first half of 2019.
"Management is pleased with the financial performance for the second quarter of this year. A robust management response to the Covid pandemic enabled all aspects of our Operations to continue with little disruption", said Derek S. Webb, President and CEO. "While we continue to be cautious regarding potential future disruptions in our supply chain and on construction sites due to a possible resurgence of the virus, the outlook for the rest of the year looks positive and is expected to meet with our expectations".
"New orders have continued to be secured, with approximately $7.7 million being closed in the second quarter. This results in the BIOREM order backlog being $30.9 million on June 30, 2020. This provides a strong foundation for revenue over the next twelve months."
Cash on hand increased during the quarter to $8.0 million from $6.5 million on March 31, 2020. Earnings from operating activities generated $507,000 of cash and a reduction in non-cash working capital added a further $992,000 of cash.
https://www.prnewswire.com/news-releases/biorem-reports-2020…
Gross profit for the quarter was $1.4 million or 23.9% of revenue compared to $1.3 million of gross profit representing 22.5% of revenue recorded during the second quarter of 2019. Total operating expenses (net of other income) for the quarter were $961,000 against $1,079,000 in the same period the prior year. The decrease in operating expenses was primarily due to a decrease in sales travel expenses related to the Covid19 pandemic. Ebitda for the quarter was $504,000 compared to $295,000 of ebitda in the second quarter of 2019.
Net earnings for the quarter were $338,000, with year to date earnings totalling $801,000 compared to net earnings of $139,000 for the first half of 2019.
"Management is pleased with the financial performance for the second quarter of this year. A robust management response to the Covid pandemic enabled all aspects of our Operations to continue with little disruption", said Derek S. Webb, President and CEO. "While we continue to be cautious regarding potential future disruptions in our supply chain and on construction sites due to a possible resurgence of the virus, the outlook for the rest of the year looks positive and is expected to meet with our expectations".
"New orders have continued to be secured, with approximately $7.7 million being closed in the second quarter. This results in the BIOREM order backlog being $30.9 million on June 30, 2020. This provides a strong foundation for revenue over the next twelve months."
Cash on hand increased during the quarter to $8.0 million from $6.5 million on March 31, 2020. Earnings from operating activities generated $507,000 of cash and a reduction in non-cash working capital added a further $992,000 of cash.
https://www.prnewswire.com/news-releases/biorem-reports-2020…
Market Cap 15.078M
Cash 8 Millionen
und profitabel!
Cash 8 Millionen
und profitabel!
Antwort auf Beitrag Nr.: 64.725.019 von pickuru am 11.08.20 18:43:23Hoi Pickuru, danke fürs Thread erstellen. Schade habe ich diese Biorem erst letzte Woche entdeckt, scheint eine rechte Perle zu sein. Bin seit heute auch dabei... Die Aktien waren schwer zu bekommen, am Freitag habe ich um den bisher bezahlten Kurs rum keine bekommen und es gab quasi kein Volumen an der TSX.
Kann mir einer die Geschäftsidee erklären?
Antwort auf Beitrag Nr.: 66.386.327 von PapaAce am 11.01.21 17:50:50
https://www.biorem.biz
Nach meinen Verständnis, bitte korrigiert mich, wenn was nicht korrekt sein sollte ☺ :
Sie bauen Anlagen für Kläranlagen und Industrie, welche verschmutze Abluft reinigen. H2S, also Wasserstoffsulfid, wird oft genannt, aber auch diverse andere Wasserlöslichen Chemikalien und Bakterien werden genannt. Es sind teils Kombifilter, mechanisch, chemisch und Bakteriell.
Das ganze ist wohl vor allem in eher dicht besiedelten Gebieten ein Thema, oder wenn es die entsprechenden Vorschriften gibt (im Falle der VOC sicherlich).
Positive Ewartungen/Fantasien sieht man im Netz, wenn man was sucht, z.B. bei yahoo finance, geb ich jetzt hier nicht wieder 😋
Zitat von PapaAce: Kann mir einer die Geschäftsidee erklären?
https://www.biorem.biz
Nach meinen Verständnis, bitte korrigiert mich, wenn was nicht korrekt sein sollte ☺ :
Sie bauen Anlagen für Kläranlagen und Industrie, welche verschmutze Abluft reinigen. H2S, also Wasserstoffsulfid, wird oft genannt, aber auch diverse andere Wasserlöslichen Chemikalien und Bakterien werden genannt. Es sind teils Kombifilter, mechanisch, chemisch und Bakteriell.
Das ganze ist wohl vor allem in eher dicht besiedelten Gebieten ein Thema, oder wenn es die entsprechenden Vorschriften gibt (im Falle der VOC sicherlich).
Positive Ewartungen/Fantasien sieht man im Netz, wenn man was sucht, z.B. bei yahoo finance, geb ich jetzt hier nicht wieder 😋
Trading Spotlight
!
Dieser Beitrag wurde von CloudMOD moderiert. Grund: Löschung auf Wunsch des Users
Biorem ist nun auch frisch bei Stocktwits aufgeschaltet
Die Jahreszahlen sind raus, fielen sehr positiv aus... gerade wenn man das schwierige Umfeld bedenkt, welches es nicht einfach macht vor Ort bei Kunden Installationen zu machen.
https://www.biorem.biz/biorem-reports-2-1-million-earnings-f…
TWELVE MONTHS ENDED DECEMBER 31, 2020
For the twelve months ended December 31, 2020 revenue totaled $24.3 million compared to $20.6 million for the same twelve months in 2019. Net earnings for the year were $2.1 million compared to a net loss of $1.3 million in 2019. Earnings per share for the year was $0.05 against a loss per share of $0.03 basic and fully diluted reported in 2019.
Revenues of $24.4 million for the year represented an 18.0% increase over revenues reported the previous year. The increase in revenue was largely the result of the increased order backlog of $31 million on January 1, 2020 compared to an order backlog of $21 million on January 1, 2019. Gross profit for the year was $7.1 million, a 44% increase from gross profit of $4.8 million recorded for the year-ended December 31, 2019.
Total operating expenses for the year were $4.3 million a $1.6 million decrease from operating expenses of $5.9 million reported in 2019. The decrease in operating expenses was largely the result of $1.7 million valuation allowance recorded against accounts receivable in China in 2019 compared to net valuation allowance of $300,000 recorded in 2020.
On December 31, 2020 the Company had cash on hand of $8.9 million and working capital of $10.5 million compared to $6.5 million and $8.6 million respectively in December 31, 2019.
The Company has no long term debt.
Total order bookings for the year were $27 million, an 18% decrease in bookings over the $32.9 million booked in 2019. The Company’s order backlog stood at $31.0 million on December 31, 2020 unchanged from $31.0 million on December 31, 2019.
“Management looks forward to the next phase of the Corporation’s development” said Derek S. Webb, President and CEO. “A strong backlog; healthy bidding activity and a number of exciting new products ready for market release provides us with the tools necessary to achieve growth in the coming years “
“The organization continues to carefully plan for customer and supply chain disruptions due to on-going pandemic restrictions. While we expect some challenges with project delivery in 2021, a number of new initiatives are underway with results expected to begin to be realized towards the end of the year. All in all, a very exciting period for our company.”
https://www.biorem.biz/biorem-reports-2-1-million-earnings-f…
TWELVE MONTHS ENDED DECEMBER 31, 2020
For the twelve months ended December 31, 2020 revenue totaled $24.3 million compared to $20.6 million for the same twelve months in 2019. Net earnings for the year were $2.1 million compared to a net loss of $1.3 million in 2019. Earnings per share for the year was $0.05 against a loss per share of $0.03 basic and fully diluted reported in 2019.
Revenues of $24.4 million for the year represented an 18.0% increase over revenues reported the previous year. The increase in revenue was largely the result of the increased order backlog of $31 million on January 1, 2020 compared to an order backlog of $21 million on January 1, 2019. Gross profit for the year was $7.1 million, a 44% increase from gross profit of $4.8 million recorded for the year-ended December 31, 2019.
Total operating expenses for the year were $4.3 million a $1.6 million decrease from operating expenses of $5.9 million reported in 2019. The decrease in operating expenses was largely the result of $1.7 million valuation allowance recorded against accounts receivable in China in 2019 compared to net valuation allowance of $300,000 recorded in 2020.
On December 31, 2020 the Company had cash on hand of $8.9 million and working capital of $10.5 million compared to $6.5 million and $8.6 million respectively in December 31, 2019.
The Company has no long term debt.
Total order bookings for the year were $27 million, an 18% decrease in bookings over the $32.9 million booked in 2019. The Company’s order backlog stood at $31.0 million on December 31, 2020 unchanged from $31.0 million on December 31, 2019.
“Management looks forward to the next phase of the Corporation’s development” said Derek S. Webb, President and CEO. “A strong backlog; healthy bidding activity and a number of exciting new products ready for market release provides us with the tools necessary to achieve growth in the coming years “
“The organization continues to carefully plan for customer and supply chain disruptions due to on-going pandemic restrictions. While we expect some challenges with project delivery in 2021, a number of new initiatives are underway with results expected to begin to be realized towards the end of the year. All in all, a very exciting period for our company.”
Schon ein paar Tage alt: Q1-2021 Report: https://www.biorem.biz/biorem-reports-first-quarter-2021-fin…
- Starker Rückgang der Umsätze in dem Quartal wegen Bauverzögerungen wegen Covid 19 - und entsprechend ein Minus in Q1
- Orderbook ist mit 30.5mCAD (ca. 1 1/2 Jahresumsätze) aber weiterhin gut gefüllt. In Q1 gab es Neubestellungen für 2.8mCAD
- Kurs ging nach den Q1 Zahlen um >10% zurück
--> Jetzt geht es darum den Rückstand aufzuholen.
- Starker Rückgang der Umsätze in dem Quartal wegen Bauverzögerungen wegen Covid 19 - und entsprechend ein Minus in Q1
- Orderbook ist mit 30.5mCAD (ca. 1 1/2 Jahresumsätze) aber weiterhin gut gefüllt. In Q1 gab es Neubestellungen für 2.8mCAD
- Kurs ging nach den Q1 Zahlen um >10% zurück
--> Jetzt geht es darum den Rückstand aufzuholen.
Aktuelle Lage aus meiner Sicht:
MK: 18.3mCAD
Gewinn 2020 2.1mCAD
Schulden: Keine
Cash >10mCAD
Auftragsbestand >30mCAD
Free Float nur 38%
= Viel Potential vorhanden, ABER:
- Leider extrem weniger Handelsvolumen
- Wenig/keine Öffentlichkeitsarbeit
- Bisher kein Plan kommuniziert was mit dem Ertrag geschehen soll. Im SmallCaps Interview wurde ein Firmenkauf als Möglichkeit angedeutet, aber da ist wohl noch alles offen.
- Zu diesen Themen habe ich sie mal angeschrieben. Wenn ich eine Antwort bekomme, kommt es hier rein.
MK: 18.3mCAD
Gewinn 2020 2.1mCAD
Schulden: Keine
Cash >10mCAD
Auftragsbestand >30mCAD
Free Float nur 38%
= Viel Potential vorhanden, ABER:
- Leider extrem weniger Handelsvolumen
- Wenig/keine Öffentlichkeitsarbeit
- Bisher kein Plan kommuniziert was mit dem Ertrag geschehen soll. Im SmallCaps Interview wurde ein Firmenkauf als Möglichkeit angedeutet, aber da ist wohl noch alles offen.
- Zu diesen Themen habe ich sie mal angeschrieben. Wenn ich eine Antwort bekomme, kommt es hier rein.
BIOREM Announces Proposed Purchase for Cancellation of Common Shares Held by TPFG Environment Investment Limited
https://finance.yahoo.com/news/biorem-announces-proposed-pur…
https://finance.yahoo.com/news/biorem-announces-proposed-pur…
Antwort auf Beitrag Nr.: 68.975.716 von pickuru am 06.08.21 08:21:06Autsch, ich war jetzt ein halbes Jahr sehr geduldig, fast schon gleichgültig... habe aber meine Aktien mühsehlig (Volumen i.d.R. kleiner als meine Aktienzahl) über die letzten 2 Wochen verkauft, weil mir hier zu wenig ging und die Firma nicht auf meine Anfragen antwortete... und dann dieser 50+% Sprung :-(
Antwort auf Beitrag Nr.: 68.975.716 von pickuru am 06.08.21 08:21:06Was denkst du Pikcuru, sind die Hintergründe des Aktienrückkaufes, respektive des Ausstiegs dieses Investors? Das waren doch die Asiaten, wo BRM gross wachsen wollte? Ok, Float geringer, aber dann ist wohl auch das Projekt Wachsen in Asien gestorben?
Biorem Shareholders Approve Purchase for Cancellation of Common Shares Held by TPFG Environment Investment Limited
https://finance.yahoo.com/news/biorem-shareholders-approve-p…
https://finance.yahoo.com/news/biorem-shareholders-approve-p…
BIOREM Announces the Novel Application of its Biological Reactors to a New Market Segment
https://finance.yahoo.com/news/biorem-announces-novel-applic…
https://finance.yahoo.com/news/biorem-announces-novel-applic…
BIOREM Announces Several Orders Totalling $9.2 Million and Order Backlog of $34.6 Million
https://finance.yahoo.com/news/biorem-announces-several-orde…
https://finance.yahoo.com/news/biorem-announces-several-orde…
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +0,41 | |
| -0,79 | |
| +1,83 | |
| -1,43 | |
| +0,71 | |
| -0,93 | |
| -0,33 | |
| +0,11 | |
| -1,65 | |
| +1,94 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 243 | ||
| 98 | ||
| 89 | ||
| 80 | ||
| 75 | ||
| 47 | ||
| 38 | ||
| 37 | ||
| 34 | ||
| 33 |
